YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
SUNNYVALE, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corpor…
The congestive heart failure market is expected to witness steady growth over the coming years, driven by the rising prevalence of cardiovascular diseases, an aging global population, and increasing awareness of early diagnosis and disease…
(RTTNews) - Biotech companies are seeing significant pre-market activity this Monday, hinting at possible breakout opportunities. Assessing sentiment and momentum in the premarket sets the tone for a trader's day. Price swings ahead of the…
Healthcare stocks rose late Friday afternoon with the NYSE Healthcare Index increasing 0.6% and the PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium ne…
Healthcare stocks rose Friday afternoon, with the NYSE Healthcare Index increasing 1.2% and the Stat PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
(RTTNews) - BioCardia, Inc. (BCDA) announced that the U.S. FDA has confirmed the company's pivotal Phase 3 CardiAMP Heart Failure II (HF II) trial may serve as the basis for a Premarket Approval (PMA) application for its CardiAMP Cell Ther…
(RTTNews) - BioCardia Inc. (BCDA), on Friday announced the receipt of a Consultation Record from the Japanese Pharmaceutical and Medical Devices Agency (PDMA) to support regulatory approval of the CardiAMP Cell Therapy for the treatment of…
Earnings Call Insights: BioCardia (BCDA) Q1 2026 MANAGEMENT VIEW * "We have had significant accomplishments this last quarter for our CardiAMP Cell Therapy for the treatment of ischemic heart failure" (CEO, President & Director Peter Altma…
SUNNYVALE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corpora…
(RTTNews) - BioCardia Inc. (BCDA), a clinical-stage regenerative medicine company, on Friday announced alignment with the U.S. food and drug administration after a pre-submission meeting on the Helix transendocardial delivery catheter syst…
(RTTNews) - BioCardia Inc. (BCDA) announced it has submitted data from its CardiAMP Heart Failure (HF) clinical study to the U.S. FDA and formally requested a meeting to discuss an accelerated approval pathway. The company expects this mee…
Earnings Call Insights: BioCardia (BCDA) Q4 2025 MANAGEMENT VIEW * Peter Altman, CEO, highlighted that BioCardia now has complete and final data from three clinical trials of CardiAMP cell therapy, with the latest Phase III results present…
SUNNYVALE, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corpo…
SUNNYVALE, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the FDA has accepted i…
(RTTNews) - Biotech and healthcare names were among the notable movers in Wednesday's after-hours trading session, with several small-cap companies posting sharp gains. IO Biotech, Inc. (IOBT) surged 19.36% to $0.25 after announcing that i…
SUNNYVALE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces it will participate…
SUNNYVALE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces the appointment of F…
BioCardia, Inc. SUNNYVALE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces the…
(RTTNews) - BioCardia, Inc. (BCDA) released Loss for third quarter that decreased from the same period last year and beat the Street estimates. The company's earnings came in at -$1.48 million, or -$0.24 per share. This compares with -$1.7…
SUNNYVALE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the…
SUNNYVALE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corpor…
Dublin, Oct. 21, 2025 (GLOBE NEWSWIRE) -- The "BioCardia Inc. (BCDA) - Product Pipeline Analysis, 2025 Update" has been added to ResearchAndMarkets.com's offering. BioCardia Inc is at the forefront of regenerative medicine, focusing on dev…
BioCardia, Inc. SUNNYVALE, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announces it has regaine…
SUNNYVALE, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announces it has regained compliance wit…
* BioCardia (NASDAQ:BCDA [https://seekingalpha.com/symbol/BCDA]) on Thursday announced the pricing of a public offering of an aggregate of 4.8M shares of its common stock and short-term warrants to purchase up to 4.8M shares of common stoc…
SUNNYVALE, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA] (“BioCardia” or the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today an…
SUNNYVALE, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the primary endpoint re…
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in CleanSpark Inc (Symbol: CLSK), where a total volume of 108,050 contracts has been traded thus far today, a contract volum…
SUNNYVALE, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- - BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that BioCardia’s Pres…
Company Logo Key drivers include rising cybersecurity threats, increased use of web-based applications, and stringent data protection laws. Businesses are heavily investing in WAF solutions to safeguard digital assets, ensure regulatory co…
Earnings Call Insights: BioCardia, Inc. (BCDA) Q2 2025 MANAGEMENT VIEW * Peter A. Altman, President and CEO, reported the completion of the CardiAMP Heart Failure trial and noted its primary outcomes were presented as a late-breaking clini…
* BioCardia press release [https://seekingalpha.com/pr/20196192-biocardia-reports-second-quarter-2025-business-highlights-and-financial-results] (NASDAQ:BCDA [https://seekingalpha.com/symbol/BCDA]): Q2 GAAP EPS of -$0.40. * Net cash used i…
SUNNYVALE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the…
SUNNYVALE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corpor…
SUNNYVALE, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today provides the anticipated timi…
Investing.com – U.S. stocks were mixed after the close on Thursday, as gains in the Oil&Gas, Industrials and Basic Materials sectors led shares higher while losses in the Technology, Telecoms and Consumer Services sectors led shares lower.…